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Abstract
Background: Blood-stasis syndrome (BSS) is one of the Traditional Chinese medicine (TCM) syndrome
differentiations that are commonly seen in stroke and ischemic heart diseases; however, the BSS differentiation
criterion is not standardized. More objective biomarkers for BSS diagnosis are needed.
Methods: Acute ischemic stroke (AIS) or unstable angina (UA) patients with BSS and healthy controls were
enrolled. The miRNA and mRNA expression profiles of UA patients and AIS patients were compared to those of
healthy controls to identify the differentially expressed miRNA and mRNA of BSS. Bioinformatics analysis was used
to identify significantly deregulated miRNAs and mRNAs correlated to BSS. QRT-PCR was performed to validate the
bioinformatics analysis results.
Results: Approximately 401 mRNAs and 11 miRNAs were differentially expressed in both UA and AIS patients
compared to healthy controls. Gene ontology (GO) functional analysis was performed, and multiple GO terms were
enriched. Among the overlapping DE miRNAs and mRNAs, miR-146b-5p, -199a-5p and 23 targeted mRNAs were
pivotal genes in the BSS genomic characteristics. These 2 miRNAs and 23 mRNAs formed network-type biomarkers
for BSS.
Conclusions: The genomic characteristics of BSS were shown in this study. miR-146b-5p, -199a-5p and the 23
targeted mRNAs formed a diagnostic network for BSS. Further improvement and validation of this diagnostic
network might lead to more objective diagnostic criteria for BSS.
Background
Atherosclerosis (AS) is a pathological process that could
affect the systemic blood vessels. Cerebrovascular- and
cardiovascular-related AS could lead to severe diseases,
such as stroke and myocardial infarction. Stroke and
ischemic heart disease (IHD) are the major causes of
death and long-term disability worldwide. According to
World Health Organization (WHO) [1], IHD and cere-
brovascular disease are the top 2 leading causes of death
at all ages, contributing to 12.2 and 9.7% of all deaths.
Despite these concerns and efforts devoted to preventing
and treating cardiovascular and cerebrovascular diseases,
the death rate increased significantly from 1990 to 2013
[2]. Continuous research on the underlying mechanism
and treatment optimization are needed for AS-related
stroke and IHD.
The pathology and mechanism of stroke and IHD are
similar to a certain extent. Ischemic stroke (IS) and IHD
are mainly caused by local vascular AS. Local inflamma-
tion, increased blood viscosity, hemodynamic abnormal-
ities and hyperlipidemia could accelerate the stimulation
of lipids and deteriorate the vascular function. Even with
a comprehensive understanding of AS, the prevention
and treatment of IS and IHD are not currently pos-
sible. Traditional Chinese Medicine (TCM) might help
to combat stroke and IHD. It has been proven that
TCM could improve the clinical symptoms and prog-
nosis of IS and IHD [3–8]. The utilization of TCM in
the world is increasing as the efficacy of TCM has
been acknowledged [9, 10].
To maximize the efficacy of TCM treatment, an accur-
ate estimation of syndrome differentiation is crucial
because it guarantees the accurate judgment of the dis-
ease and the application of the herbal formula or patent
medicine. Syndrome differentiation is also a large chal-
lenge for practitioners to fully apprehend TCM because
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the standard of syndrome differentiation is either not
determined or too subjective. According to a number of
surveys, the main syndrome of IS and IHD is Blood-
Stasis syndrome (BSS). One web-based survey in Korea
reported that the most common difficulty (52.5 %) in
diagnosing BSS for doctors in Korea was “the lack of an
objective measurement method,” and more than half
(88.9 %) of the participants thought that an objective
diagnostic method for BSS was necessary [11]. Current
estimations of BSS are mostly based on clinical symp-
toms [11, 12], and seeking a reliable biomarker for BSS
and other syndromes is one of the hot spots in TCM
research [13–15].
Messenger RNA (mRNA) and microRNA (miRNA)
might be potential biomarkers for BSS. miRNA is an en-
dogenous, non-protein coding, single-stranded, small
RNA that is generally regarded as negative regulator of
gene expression by inhibiting translation and/or promot-
ing mRNA degradation [16]. Research has shown that
the expression of mRNA and miRNA varies in different
syndromes of diseases [17–22], and the patterns and
interactions between mRNA and miRNA may provide
an approach to estimate the syndrome differentiation.
In this study, we used microarray profiling and bio-
informatics to investigate miRNA-mRNA expression
patterns in BSS patients to gain insight into BSS and
provide potential biomarkers for BSS in the treatment of
IS and IHD such that the utilization of TCM would be
relatively convenient and more accurate. The miRNA
and mRNA expression profiling of BSS unstable angina
(UA) patients and acute ischemic stroke (AIS) patients
were compared to healthy controls to identify the differ-
entially expressed miRNA and mRNA of BSS. Bioinfor-
matics analysis was used to identify significantly




Twenty patients with UA and 20 patients with AIS were
recruited in Guang’anmen Hospital, Beijing, China. All
of their TCM syndrome differentiations were BSS. The
diagnosis of coronary artery disease (CAD) was con-
firmed in all UA patients by coronary angiography, with
at least one vessel lesion (>50 % narrowing of luminal
diameter). All UA patients met the American College
of Cardiology/American Heart Association (ACC/
AHA) criteria for UA [23] and experienced ischemic
chest pain within 48 h before recruitment, including
angina pectoris with an accelerating pattern or pro-
longed duration (>20 min) or recurrent episodes at
rest or with minimal effort, but with no evidence of
enzymatic criteria. ECG showed ST segment deviation
and/or T wave inversion. For patients undergoing
percutaneous coronary intervention, blood samples
were taken before this procedure.
All AIS patients met the American Heart Associ-
ation/American Stroke Association (AHA/ASA) cri-
teria for AIS [24], as confirmed by brain CT or MRI
scan. All AIS patients had experienced focal neuro-
logical symptoms within 48 h before recruitment, in-
cluding dysphagia, dysarthria, hemianopsia, limb
weakness, ataxia, sensory loss and spatial neglect, but
their consciousness was generally clear or slightly
damaged.
The diagnosis of BSS was based on a grading sys-
tem drafted by the committees of the International
Conference on Blood Stasis Syndrome (October, 1988,
Beijing, China), which has been used in China for
more than 2 decades [12, 25]. It has 33 items for
diagnosis, including symptoms, signs, and laboratory
tests (Table 1). If the grading point of BSS in a pa-
tient is greater than 19, the patient should be diag-
nosed with BSS. The diagnosis of BSS was made by 3
appointed senior TCM practitioners. Patients were
included in the study only if the 3 practitioners
reported consistent results, which ensured that all of
the selected patients had the typical manifestations of
BSS.
Patients who had received thrombolytic therapy in
the previous month or with MI, heart failure, valvular
heart disease, dilated cardiomyopathy, malignant
tumor, advanced liver disease, renal failure, auto-
immune diseases, and other inflammatory diseases
and women who were pregnant or breast-feeding
were excluded from the study. Patients in the UA
group with stable angina and patients in the AIS
group with acute cerebral hemorrhage, subarachnoid
hemorrhage, and stable or unstable angina pectoris
were excluded from the study. Control subjects (n =
20) were healthy volunteers recruited from the same
population and the same area of China as the pa-
tients’ group. Five subjects in every group were ran-
domly allocated in microarray profiling and the other
15 subjects underwent qRT-PCR verification.
Plasma collection and RNA isolation
Whole blood samples (10 mL) were drawn from each of
the 60 participants (20 from the UA group, 20 of AIS
group and 20 healthy volunteers/blank group) with a 19-
gauge needle for the clean venipuncture of antecubital
vein on the morning following hospitalization. The
blood samples were collected within 24 h of the onset of
chest pain in UA patients and within 24 h of the
hospitalization in AIS patients. Blood was drawn into
EDTA-containing tubes and peripheral blood mono-
nuclear cells (PBMCs) were isolated by density gradient
centrifugation with Ficoll (Invitrogen, Carlsbad, CA,
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USA). Total RNAs were extracted from PBMCs using
Trizol reagent (Invitrogen) according to the manufac-
turer’s instructions. RNA quantity and purity were
assessed using NanoDrop ND-1000 (Thermo Scientific,
Waltham, MA, USA). Passing criteria for absorbance
ratios were established at A260/A280≥1.8 and A260/
A230≥1.5 indicating acceptable RNA purity. RNA Integ-
rity Number (RIN) values were ascertained using Agilent
RNA 6000 Nano assay (Agilent Technologies, Santa Clara,
CA, USA). Passing criteria for the RIN value were estab-
lished at ≥6 indicating acceptable RNA integrity. Genomic
DNA contamination was evaluated by gel electrophoresis.
The RNA samples were stored at −80 °C before analysis.
mRNA expression profiling
Total RNAs were used for mRNA expression profiling
by the Human Whole Genome OneArray v5 (Phalanx
Biotech Group, Hsinchu, Taiwan). It contained 30,275
DNA oligonucleotide probes, and each probe was a 60-
mer designed in the sense direction. Approximately
29,187 probes corresponded to the annotated genes in
RefSeq v38 and Ensembl v56 database, and 1088 probes
were control probes. Fluorescent aRNA targets were
prepared from 1 or 2.5 μg total RNA samples using the
OneArray Amino Allyl aRNA Amplification Kit (Phalanx
Biotech Group) and Cy5 dyes (Amersham Pharmacia,
Piscataway, NJ, USA). Fluorescent targets were hybridized
to the Human Whole Genome OneArray with Phalanx
hybridization buffer using the Phalanx Hybridization Sys-
tem. After 16 h of hybridization at 50 °C, nonspecific
binding targets were washed away by three different wash-
ing steps (Wash I 42 °C 5 min; Wash II 42 °C 5 min, 25 °C
5 min; Wash III rinse 20 times), and the slides were dried
by centrifugation and scanned by an Axon 4000B scanner
(Molecular Devices, Sunnyvale, CA, USA). The intensities
of each probe were obtained by GenePix 4.1 software
(Molecular Devices). The raw intensity of each spot was
loaded into Rosetta Resolver System (Rosetta Biosoftware,
Seattle, WA, USA) to process data analysis. The error
model of Rosetta Resolver System could remove both sys-
tematic and random errors form the data. Those probes
with background signals were filtered out. Probes that
passed the criteria were normalized by a 50 % median
scaling normalization method. Normalized spot intensities
were transformed to mRNA expression log2 ratios.
microRNA expression profiling
miRNA expression profiling was performed in the same
set of samples in the mRNA microarray analysis. The
Human miRNA OneArray v4 (Phalanx Biotech Group)
was used. It contained triplicated 1884 unique miRNA
probes from humans (miRBase Release v18), each
printed in technical triplicate, and 144 experimental
control probes. Small RNA was pre-enriched by Nano-
seplook (Pall Corporation, Port Washington, NY, USA)
from 2.5 μg total RNA samples and labeled with the
miRNA ULS Labeling Kit (Kreatech Diagnostics,
Table 1 The grading system in quantifying blood stasis
syndrome diagnosis standards
Signs and symptom Point
Purple tongue (less severe) 8, (more severe) 10
Resistance to pressure
in lower abdomen
(less severe) 8, (more severe) 10
Choppy pulse 10










Hypodermal ecchymoses (less severe) 8, (more severe) 10
Dark menstrual blood
with clots
(less severe) 8, (more severe) 10
Persistent angina pectoris 10
General fixed pain 8






(less severe) 4, (more severe) 5
Paralysis in extremities (less severe) 5, (more severe) 7
Psychiatric abnormality (Irritability) 4, (Mania) 8
Rough skin (less severe) 4, (more severe) 5
Complete blood viscosity (+) 10
Blood plasma viscosity (+) 5
External clot net weight (+) 10
External clot total weight (+) 8
Increase in platelet aggregation 10





Decrease in fiber dissolution
activity
10
Resistance in platelet release 10
Pathogenic scan (+) for
blood stasis
10
Blood vessel obstruction by
new technology analysis
10
Grades >19 points are categorized as Blood-Stasis syndrome
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Vierweg, Amsterdam, The Netherlands). Labeled miRNA
targets were hybridized to the Human miRNA OneArray
v4 with OneArray Hybridization System. After 16 h of
hybridization at 37 °C, nonspecific binding targets were
washed away by three different washing steps (Wash I
37 °C 5 min; Wash II 37 °C 5 min, 25 °C 5 min; Wash
III rinse 20 times), and the slides were dried by centrifu-
gation and scanned by an Axon 4000B scanner (Molecular
Devices). The Cy5 fluorescence intensities of each probe
were analyzed by GenePix 4.1 software (Molecular
Devices). The raw intensity of each probe was processed
by the R program. Probes that passed the criteria were
normalized by the 75 % median scaling normalization
method. Normalized spot intensities were transformed to
miRNA expression log2 ratios.
Identification of differentially expressed genes
The Limma package [26] in R software (Version 3.1.1)
was used to compare the normalized probeset intensities
between the blank group and the UA group as well as
the blank group and the AIS group. The threshold of
miRNA comparison was set as P < 0.05 and fold change
>0.8, while the threshold of mRNAs comparison was set
as P < 0.05 and fold change >1 (to concentrate on those
mRNAs that interact more with miRNAs). The Annotate
package was used to annotate the differentially expressed
genes (DE genes).
Bioinformatic analysis
To identify the pivotal and characteristic genes of BSS,
the DE mRNAs and miRNAs of the blank group vs. the
UA group and the blank group vs. the AIS group were
pooled together for profound analysis. The overlapped
mRNAs and miRNAs of two sets of DE genes were iden-
tified. Database for Annotation, Visualization, and Inte-
grated Discovery (DAVID) [27] online tools (http://
david.abcc.ncifcrf.gov/home.jsp) was applied to annotate
and analyze the GO enrichment of DE genes. The
threshold was set as P < 0.05. MiRWalk 2.0 database [28]
was used to predict the target mRNAs of overlapped
miRNAs. The DIANA-mT, miRanda, miRWalk and
TargetScan programs were applied. If the prediction was
identified in no less than 3 programs, the prediction was
considered solid. Those targeted miRNA-mRNAs found
in both overlapped DE mRNA and miRNA sets were
screened out. STRING (Version 9.1) online tools (http://
www.string-db.org/) and Cytoscape (Version 3.1.1) [29]
were used to construct and visualize the mRNA-GO
terms network and the miRNA-mRNA targeting
network.
qRT-PCR validation of pivotal mRNAs and miRNAs
With the bioinformatics analysis of the DE mRNAs and
miRNAs, miR-146b-5p and -199a-5p were the pivotal
genes in the BSS-associated characteristic network and
merited further investigation. Thus, real-time quantita-
tive polymerase chain reaction (qRT-PCR) of miR-146b-
5p and miR-199a-5p was performed to validate the
bioinformatics analysis results in an independent cohort
of 15 UA patients, 15 AIS patients and 15 healthy con-
trols in accordance with the microarray subjects.
QRT-PCR was performed according to the manufac-
turer’s instructions (System Biosciences, Mountain View,
CA, USA) with 2X SYBR Green qPCR Mastermix
(Roche Applied Science, Indianapolis, IN, USA) and a
7900HT Fast Real-Time PCR System (Applied Biosys-
tems, Carlsbad, CA, USA). The primer sequences of
miR-146b-5p, miR-199a-5p and Human U6 snRNA (in-
ternal control) were as follows: miR-146b-5p: forward
5′-TGA GAA CTG AAT TCC ATA GGC T-3′; miR-
199a-5p: forward 5′-CCC AGT GTT CAG ACT ACC
TGT TC-3′; Human U6 snRNA: forward 5′-CGC AAG
GAT GAC ACG CAA ATT C-3′. The thermal cycling
conditions were 95 °C for 5 min, followed by 40 cycles
of 95 °C for 30 s, 55 °C for 30 s, 72 °C for 50 s, and a
final extension at 72 °C for 8 min. The relative expres-
sion fold change of target genes was calculated using the
comparative CT method with the 2−ΔΔCT equation.
Results
Clinical characteristics of participants
A total of 60 subjects were recruited for this study and
divided into 2 cohorts. The microarray cohort included
5 UA patients, 5 AIS patients and 5 healthy controls.
The qRT-PCR validation cohort included 15 UA
patients, 15 AIS patients and 15 healthy controls. The
clinical characteristics of the 2 cohorts were listed in
Tables 2 and 3. The 3 groups in both cohorts were
matched in terms of age, sex, BMI (body mass index),
CRP (C-reactive protein) and most of the blood lipids
(P > 0.05).
DE mRNAs and miRNA identification
The DE mRNAs and miRNAs between the blank group
and the UA group and the blank group and the AIS
group were screened out via the limma package in R
software. In the comparison between the blank group
and UA group, there were 1151 DE mRNAs and 27 DE
miRNAs. Among these, 731 (63.51 % of all the DE
mRNAs) mRNAs were up-regulated in the UA group
and 420 (36.49 % of all DE mRNAs) mRNAs were
down-regulated. Meanwhile, 25 (92.6 % of all the DE
miRNAs) miRNAs were up-regulated and 2 (7.4 % of all
the DE miRNAs) miRNAs were down-regulated. In the
comparison between the blank group and AIS group,
there were 585 DE mRNAs and 22 DE miRNAs. Among
these, 416 (71.11 % of all the DE mRNAs) mRNAs were
up-regulated in the AIS group and 169 (28.89 % of all
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DE mRNAs) mRNAs were down-regulated. All of the
DE miRNAs were up-regulated and none of the miRNAs
were down-regulated.
Overlapped DE miRNAs and mRNA identification
The two sets of DE mRNAs and miRNAs represent the
characteristics of BSS in two different diseases. Apart
from the differences of UA and AIS, there were similar-
ities between those two groups of patients. Both of them
were diagnosed with BSS in the perspective of TCM.
To seek the intersections of UA and AIS is to seek
the general and common features of BSS. In the the-
ory of TCM, it is called “the same syndrome in differ-
ent diseases.” To this end, we pooled the two sets of
DE mRNAs and miRNAs together and screened out
the overlapped mRNAs and miRNAs. There were 304
up-regulated mRNAs, 97 down-regulated mRNAs and
11 up-regulated miRNAs, from which may we find
the common features and pathological mechanisms of
BSS and provide potential biomarkers in the diagnosis
of BSS.
Functional analysis of overlapped DE miRNAs and mRNAs
The total of 401 overlapped DE mRNAs were uploaded
to DAVID online tools to analyze the enrichment of GO
terms. A total of 31 GO terms were significantly
enriched. The details of the GO terms were listed in
Table 4. The functional network of GO terms and the
involved DE mRNAs was constructed and visualized via
cytoscape (Fig. 1).
Target prediction of overlapped DE miRNAs and mRNAs
MiRWalk was used to predict the target mRNAs of the
11 up-regulated miRNAs, and thousands of miRNA-
mRNA targeting predictions were obtained. miRNAs
were usually negatively correlated with target mRNAs.
Since all the overlapped DE miRNAs were up-regulated,
we cross-referenced the predicted mRNA with the
down-regulated DE mRNA. Eventually, we identified 2
miRNAs and 23 targeted DE mRNAs as the miRNA-
mRNA targeting network of BSS. The visualization of
miRNA-mRNA interactions is shown in Fig. 2.
Table 2 Clinical characteristics of microarray subjects
Controls (n = 5) UA (n = 5) AIS (n = 5) P value
Male (n) 3 3 3
Age (years) 52.60 ± 7.40 56.40 ± 6.95 58.00 ± 7.18 0.571
BMI (kg/m2) 23.24 ± 1.62 23.18 ± 3.89 22.58 ± 2.76 0.320
BSS Grades 0 72.80 ± 10.47 78.60 ± 2.61 0.000
Hypertension (n) 0 4 5 0.000
Type 2 diabetes mellitus (n) 0 0 0
Total cholesterol (mmol/L) 4.02 ± 0.79 4.18 ± 0.89 4.24 ± 0.77 0.964
LDL cholesterol (mmol/L) 2.51 ± 0.60 2.33 ± 1.01 2.74 ± 0.63 0.871
HDL cholesterol (mmol/L) 1.29 ± 0.30 1.33 ± 0.35 1.04 ± 0.17 0192
Triglycerides (mmol/L) 1.09 ± 0.34 1.15 ± 0.50 1.79 ± 0.88 0.247
CRP (mg/L) 1.82 ± 0.78 2.84 ± 1.74 3.37 ± 1.66 0.316
Table 3 Clinical characteristics of qRT-PCR subjects
Controls (n = 15) UA (n = 15) AIS (n = 15) P value
Male (n) 10 11 9 0.838
Age (years) 56.87 ± 6.70 57.53 ± 6.33 53.07 ± 5.87 0.182
BMI (kg/m2) 21.80 ± 2.20 23.85 ± 1.81 22.53 ± 2.78 0.092
BSS Grades 0 68.60 ± 8.72 67.93 ± 9.88 0.000
Hypertension (n) 0 11 14 0.000
Type 2 diabetes mellitus (n) 0 6 3 0.018
Total cholesterol (mmol/L) 3.71 ± 0.76 4.28 ± 0.89 4.60 ± 0.87 0.072
LDL cholesterol (mmol/L) 2.37 ± 0.54 2.66 ± 0.63 2.92 ± 0.64 0.056
HDL cholesterol (mmol/L) 1.37 ± 0.29 1.31 ± 0.31 1.14 ± 0.19 0.112
Triglycerides (mmol/L) 1.03 ± 0.28 2.46 ± 1.03 1.82 ± 1.09 0.000
CRP (mg/L) 3.97 ± 1.86 4.84 ± 2.10 4.57 ± 2.34 0.682
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qRT-PCR validation of DE miRNAs
The qRT-PCR results of miR-146b-5p and miR-199a-5p
in the validation cohort are presented in Fig. 3. miR-
146b-5p and miR-199a-5p were upregulated both in the
UA and AIS groups compared to the healthy control
group (P < 0.01). Such results coincided with the micro-
array profiling and bioinformatics analysis.
Discussion
TCM has been proven to be effective as complemen-
tary and alternative medicine in treating cerebrovas-
cular and cardiovascular diseases. The key to utilizing
TCM appropriately and maximizing its efficacy is to
accurately apprehend syndrome differentiation. Therefore,
a standard diagnostic criterion with objective indexes is
needed. Comprehensive whole-genome screening of the
transcriptome has previously suggested that disease-
specific mechanisms are distinguishable [30–32]. Syn-
drome differentiations could be characterized by the
expression of different genes [17–22]. Using microarray
profiling and bioinformatics to investigate the gene ex-
pression patterns of BSS could illuminate the pathological
mechanisms of BSS and provide potential biomarkers for
clinical diagnosis.
Recent studies have demonstrated that miRNAs can
circulate in systemic blood in a remarkably stable form
[33]. It is possible to use the circulating miRNA expres-
sion patterns as biomarkers for the differentiation of
syndromes such as BSS. With the auxiliary miRNA’s tar-
get genes, a syndrome-related miRNA-mRNA network
could be constructed.
In this study, the microarray profiling comparison be-
tween the blank group and the UA group showed patho-
logical changes of UA from the genomic level, along
with the blank group and AIS group. The DE mRNAs
and miRNAs indicated the characteristics of UA and
AIS with BSS. When we focused on the similarities of
BSS in different diseases (the same syndrome in different
diseases), we merged and screened out the overlapped
DE mRNAs and miRNAs in the two comparisons. The
401 overlapped DE mRNAs and 11 miRNAs represent
the genomic characteristics of BSS beyond diseases. The
GO analysis of the 401 overlapped DE mRNAs showed
the biological processes involved in BSS. Basic life activ-
ities and processes were the major enriched terms, in-
cluding transcription (GO:0006351, P = 0.000087),
regulation of transcription (GO:0006355, P = 0.00011),
protein kinase cascade (GO:0035556, P = 0.00038), and
protein amino acid phosphorylation (GO:0006468,
0.0032). Among the top 10 GO terms sorted by P-value,
immune response (GO:0006955, P = 0.0027) and negative
regulation of apoptosis (GO:0043066, P = 0.0036) might
be the pivotal pathological processes related to BSS.
The 11 overlapped DE miRNAs were the candidates for
biomarkers of BSS. Among the multiple functions and tar-
gets of miRNA, cardiovascular- and cerebrovascular-
related studies were searched specifically. a) miR-221-3P:
miR-221-3p was up-regulated in the patients with ische-
mic stroke [34] and acute coronary syndrome and was
correlated with plasma and platelets [35]. b) miR-150:
miR-150 was significantly related to immune response,
and its increase in serum was correlated with the elevation
of antibody titers [36]. A previous study reported that
miR-150-5p, miR-1275, and miR-365a-3p were associated
with chronic heart diseases and reflected the dysregulation
of B-cell-centered immune function [37]. It was reported
that variations in the expression of miR-146a, miR-150,
Table 4 Details of the significantly enriched GO terms
Term P-Value
transcription 0.000087
regulation of transcription 0.00011
protein kinase cascade 0.00038
immune response 0.0027
protein amino acid phosphorylation 0.0032
negative regulation of apoptosis 0.0036
MAPKKK cascade 0.01
proteolysis involved in cellular protein catabolic process 0.012
modification-dependent protein catabolic process 0.014
modification-dependent macromolecule catabolic process 0.014
phosphorylation 0.018
regulation of apoptosis 0.019
regulation of T cell receptor signaling pathway 0.021
ER overload response 0.021
regulation of programmed cell death 0.022
regulation of cytokine production 0.025
cellular macromolecule catabolic process 0.029
regulation of antigen receptor-mediated signaling pathway 0.03
centrosome organization 0.037
regulation of leukocyte activation 0.039
cellular response to stress 0.039
regulation of translation 0.039
toll-like receptor signaling pathway 0.04
negative regulation of immune system process 0.043
response to endoplasmic reticulum stress 0.043
positive regulation of skeletal muscle growth 0.046
microtubule organizing center organization 0.046
ER-nuclear signaling pathway 0.046
JNK cascade 0.047
anti-apoptosis 0.05
regulation of cell size 0.05
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and miR-155 in MI compared to normal hearts were
detected, which are involved in the regulation of innate
immunity [38]. c) miR-146a-5p: miR-146a-5p has been
identified as a negative regulator in the innate immune
and inflammatory responses mediated by Toll-like receptor
(TLR) 4 and polymorphisms (miRSNPs) [39, 40]. Research
on miR-146b-5p has shown that it could reduce the
expression of TNFα via the IRAK/NFkB pathway
[39, 41]. It was reported that miR-146b-5p is linked
to the regulation of both apoptotic and anti-
apoptotic genes [42]. d) miR-199a-5p: Roncarati R et
al. compared hypertrophic cardiomyopathy (HCM)
patients with healthy controls, and the peripheral
plasma levels of miR-199a-5a and other miRNAs
were detected. miR-199a-5p was significantly in-
creased and correlated with hypertrophy [43]. These
studies helped confirm the possible relationship
between the 11 miRNAs and AIS and IHD and indi-
cated the involved functional processes.
To increase the credibility of miRNA as the biomarker
of BSS, the combination of miRNA and targeted mRNA
was applied. Among the 11 overlapped DE miRNAs,
Fig. 1 The functional network of GO terms and the involved DE mRNAs
Fig. 2 The miRNA-mRNA interactions
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only miR-146b-5p and miR-199a-5p had targeted
mRNAs, which were also present in the overlapped DE
mRNAs. Additionally, qRT-PCR validated the upregula-
tion of miR-146b-5p and miR-199a-5p in BSS patients.
Previous studies on miR-146b-5p and miR-199a-5p
demonstrated the possible mechanisms of BSS in cere-
brovascular and cardiovascular diseases. In this study,
miR-146b-5p, miR-199a-5p and their 23 targeted over-
lapped DE mRNAs formed a biomarker network for the
diagnosis of BSS. The pivotal roles of miR-146b-5p and
miR-199a-5p made them the center of the diagnostic
network of BSS, and the mRNAs validated the diagnosis.
The present study revealed that circulating miRNAs
and mRNAs might be the potential biomarkers of BSS,
and the comprehensive application of miRNAs and
mRNAs as a network might enhance the credibility of
miRNAs and mRNAs as BSS diagnostic criteria. MiR-
146b-5p and miR-199a-5p were the key miRNAs in the
diagnostic network, which might be the most valuable
biomarkers for BSS. With the help of these objective
indexes, the diagnostic criteria of BSS could be more
advanced and the apprehension of BSS diagnosis may be
easier for practitioners.
Apart from the potential clinical applications this
study has provided, it presented some limitations. The
sample sizes of both cohorts in this study were small,
especially for the microarray profiling cohort. The tran-
scriptomic analysis from such small sample sizes may
lead to fragmentary results and affect the following val-
idation cohort. The identified DE genes for BSS are pre-
liminary, the application in clinical practice was not
evaluated fully in this study. Further improvement and
retrenchment on the diagnostic network are required.
Clinical studies with more BSS participants are required
to extensively evaluate the miRNAs and mRNAs as feas-
ible biomarkers. Nevertheless, this study laid the
groundwork for identifying miR-146b-5p, miR-199a-5p,
and those targeted mRNAs as potential network-type
biomarkers for BSS. The diagnosis of BSS could be
achieved more objectively if further research could valid-
ate these results in a larger cohort of participants.
Conclusions
In general, this study presented a new approach to iden-
tify potential biomarkers for BSS via genomics and bio-
informatics. miR-146b-5p, -199a-5p and the 23 targeted
mRNAs formed a diagnostic network for BSS. With fur-
ther improvement and the validation of this diagnostic
network, more objective diagnostic criteria for BSS
might be utilized in clinical practice.
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